

Sunday, 16 May 2010

Registration

12:00 PM - 6:00 PM

Venue Foyer

Welcome

2:00 PM - 2:20 PM

Pfizer Australia Lecture Theatre

Chair: Michelle Haber

Drug Discovery - Challenges and Opportunities

2:20 PM - 3:30 PM

Pfizer Australia Lecture Theatre

Chair: Michelle Haber and Phil Robinson

Vishva Dixit

Signaling Lessons from Death Receptors abs#001

Afternoon Tea

3:30 PM - 4:00 PM

Tyree Room

Targeting Signalling Pathways

4:00 PM - 6:00 PM

Pfizer Australia Lecture Theatre
Session sponsored by CSL Ltd

Chair: Christine Clarke and Glenn Marshall

4:00pm **Laura Soucek**

Deconstructing oncogenesis and tumour suppression to find the best cancer targets abs#002

4:45pm **Clare Scott**

BH3-only proteins have crucial roles in efficacy and toxicity of cancer therapy abs#004

5:15pm **Caroline Ford**

The Wnt-5a derived Foxy-5 peptide renders insensitive breast cancer cells, responsive to Tamoxifen abs#005

5:30pm **Ricky Johnstone**

Targeting the epigenome using histone deacetylase inhibitors to induce tumor cell apoptosis and anti-cancer responses abs#003

Welcome Reception

6:00 PM - 7:30 PM

Tyree Room

Monday, 17 May 2010

Registration

8:00 AM - 5:00 PM

Venue Foyer

Novel Targets

8:30 AM - 10:30 AM

Pfizer Australia Lecture Theatre

Session sponsored by Beckman Coulter Australia

Chair: Mathew Vadas and Levon Khachigian

- 8:30am **Lyubomir Vassilev**
Targeting the p53-MDM2 interaction to treat cancer abs#006
- 9:15am **Angel Lopez**
A molecular basis for the pleiotropic biological activities of cytokine receptors abs#007
- 9:45am **Martin Lackmann**
Eph-programmed cell-to-cell communication in cancer abs#008
- 10:15am **Justine Stehn**
Tropomyosin Tm5NM1: A Novel Target for Anti-cancer Chemotherapeutics abs#009

Morning Tea

10:30 AM - 11:00 AM

Tyree Room

Poster Session

11:00 AM - 12:30 PM

Pfizer Australia Lecture Theatre

Minoti Apte

Normal pancreatic stellate cells facilitate pancreatic cancer progression, exhibit transendothelial migration and accompany cancer cells to distant metastatic sites abs#101

Greg Arndt

New High-Throughput Small Molecule Screening Facility: ACRF Drug Discovery Centre for Childhood Cancer abs#102

Alex Beesley

Drug-Gene Modelling for the Prediction of Resistance and Disease Outcome in Paediatric Acute Lymphoblastic Leukaemia abs#103

Jessica Bell

The estrogen-responsive B-box protein (EBBP/TRIM16) is a novel regulator of differentiation and tumourigenicity in neuroblastoma abs#104

Anneke Blackburn

Targeting mitochondria with arsenic trioxide and dichloroacetate in breast cancer cells. abs#105

Rose Boutros

Identifying centrin 2 and γ -tubulin as novel CDK2 substrates at the centrosome abs#106

Christopher Burns

CYT387: a potent and selective inhibitor of JAK1 and JAK2 for the treatment of myeloproliferative neoplasms and cancer abs#107

Hernan Carol

Cumulative analysis of five years of testing by the Pediatric Preclinical Testing Program against acute lymphoblastic leukaemia abs#108

Daniel Catchpoole

Vesicle Sequestration of the Novel Topoisomerase Poison, AS-DACA, Leads to Resistance in Rhabdomyosarcoma Cells abs#109

Georgia Chenevix-Trench

Common somatic mutations in genes related to the AKT/MAPK signaling pathways in breast cancer and brain metastases abs#110

Albert Chetcuti

The Expression of Interleukin-7 Signalling Pathway Proteins in Neuroblastoma abs#111

Megan Chircop

Dynamin II as a potential new anti-cancer target: inhibitors reduce tumour volume by inducing apoptosis following cytokinesis failure abs#112

Lauren Cottrell

Alterations in Protein Phosphatase 2A Expression Suggest a Tumour Suppressive Role in Breast Cancer abs#113

Pierre Dilda

A Tumour Marker for Selection of Patients That Should Better Respond to Treatment with the Australian anti-cancer drug, GSAO abs#114

Alla Dolnikov

Glycogen synthase kinase-3 β inhibitors suppress leukemia cell growth. abs#115

Claudia Flemming

Identification and characterisation of small molecule inhibitors of multidrug resistance-associated protein, MRP4 abs#116

Jamie Fletcher

Determinants of organ specific neuroblastoma metastasis abs#117

David Fung

Classification of colorectal cancer (CRC) patients using network clustering: a preliminary study abs#118

Renate Griffith

Identification and Validation of New Targets for Prostate Cancer Chemotherapy abs#119

Michelle Henderson

A new compound for targeted therapy of MLL-rearranged leukaemia. abs#120

Nicholas Ho

Data-mining gene expression and genomic microarray datasets of Acute Lymphoblastic Leukaemia abs#121

Wendy Ingram

Determining the role of ABC transporters in radiation resistant medulloblastoma abs#122

Mawar Karsa

The significance of minimal residual disease at day 15 for predicting relapse in ALL abs#123

Maria Kavallaris

β III-Tubulin is a multifunctional protein involved in in vivo drug sensitivity and tumorigenesis in non-small cell lung cancer abs#124

Guy Klamer

Investigating the potential of small molecule GSK 3-beta inhibitors to reduce the burden of GVHD after allogeneic hematopoietic stem cell transplantation abs#125

Kurt Lackovic

The Importance of Relevant In Vitro Focal Adhesion Kinase (FAK) Assays abs#126

Tamara Law

Detection of molecular relapse at end of chemotherapy in acute lymphoblastic

leukaemia abs#127

Siong Lim

Antiangiogenic effect of paclitaxel is correlated to the inhibition of RhoA activation abs#128

Louise Lutze-Mann

Modulation of cholesterol homeostasis as a novel cancer chemotherapeutic target for treating Glioblastoma? abs#129

Nicole Mackie

Identification of new proteins to determine invasion in favourable Wilms Tumour abs#130

Michelle Frances Maritz

Direct targeting of telomerase enzyme components in isogenic normal, immortal and tumorigenic cells abs#131

Nathalie Martinek

Using the fruitfly, *Drosophila melanogaster*, to model childhood brain cancers abs#132

Joshua McCarroll

Potent and stable suppression of β III-tubulin modulates the expression of proteins involved in tumourigenesis in non-small cell lung cancer abs#133

Gorjana Mitic

β III-tubulin and glioblastoma: Targeting drug resistance and tumourigenesis abs#134

Marcia Munoz

ABCC transporters influence multiple aspects of neuroblastoma biology, as well as clinical outcome, independent of cytotoxic drug efflux abs#135

Guy Nelmes

Increased ribosomal protein L38 expression is indicative of CD34+ cells present in childhood acute lymphoblastic leukaemia abs#136

Danielle Park

Non-invasive Imaging of Tumour Cell Death using a Hsp90 Ligand abs#137

Kara Perrow

Selective Targeting of Cytotoxic Drugs to Urokinase Positive Cancer Cells in vitro abs#138

Phoebe Phillips

Heat shock proteins are induced during pancreatic stellate cell activation in pancreatic cancer abs#139

Hilda Pickett

Telomere trimming in normal mammalian cells abs#140

Sharon Pok

Functional significance of cyclin E and p53 interactions in liver carcinogenesis abs#141

Pamela Pollock

FGFR as a therapeutic target in Endometrial cancer – susceptibility, synergy and resistance abs#142

Stephen Ralph

Bioenergetic pathways in tumour mitochondria as targets for cancer therapy and the ROS-induced apoptotic trigger abs#143

Marie Ranson

Preclinical evaluation of novel all-in-one parenteral formulations for the concomitant delivery of 5-fluorouracil and folinic acid with reduced toxicity profiles abs#144

Amy Samuels

Interrogating Drug Resistance using a Xenograft Model of Leukaemia Relapse abs#145

Galina Schevzov

The tropomyosin Tm5NM1 mediates regulation of cell growth by the actin cytoskeleton abs#146

Angie Shum

MEF2C: A novel regulator of cancer-induced skeletal muscle wasting abs#147

Amanda Smith

Mechanism of oncogenic c-KIT mediated inactivation of the tumour suppressor protein phosphatase 2A (PP2A) abs#148

Josh Stern

Telomerase recruitment to telomeres abs#149

Margareta Sutija

Single-well simultaneous measurement of MAP2K MEK1 activity and interaction with the MAP kinase ERK2 using AlphaScreen and AlphaLISA platforms abs#150

Rosemary Sutton

Mitoxantrone significantly improved the outcome of children with relapsed ALL enrolled on ALLR3 abs#151

Liz Valente

Pro-apoptotic Puma, and to a lesser extent Noxa, are critical for the therapeutic effects of the p53-activating compound Nutlin3a in lymphoid cells abs#152

Nicole Verrills

Activating the tumour suppressor, PP2A, as a novel therapy for acute myeloid leukaemia abs#153

Georg von Jonquieres

Telomerase activity and high levels of dyskerin in normal erythroid precursor cells abs#154

Laurence Wakelin

Mass spectrometry studies of the binding of the minor groove-directed alkylating agent alkamin and related agents to AT-tract oligonucleotides abs#155

Ben Williams

Flexible, polymer nanocapsules for the targeted delivery of chemotherapeutics to A33 antigen expressing colorectal cancer abs#156

Chengyuan Xue

Characterization of a potential small molecule inhibitor of Myc oncoproteins abs#157

Ping Ye

Development of Peptides that Inhibit the Interaction of the Myb Oncoprotein with its Coregulator CBP/p300 abs#158

Lunch

12:30 PM - 1:30 PM

Tyree Room

Chemical Biology

1:30 PM - 3:00 PM

Pfizer Australia Lecture Theatre

Session sponsored by Cancer Institute New South Wales

Chair: Phil Hogg

1:30pm

Karl Barry Sharpless

Click Chemistry in Fast Modular Drug Discovery abs#010

2:30pm

Michael Parker

Cancer structural biology and drug discovery abs#011

Afternoon Tea

3:00 PM - 3:30 PM

Tyree Room

Drug Development from Lab to Clinic I

3:30 PM - 5:00 PM

Pfizer Australia Lecture Theatre

Chair: Maria Kavallaris and Doug Hilton

3:30pm

Susan Band Horwitz

Taxol, Tubulin and Tumors abs#012

4:15pm

Steven Stacker

Vascular growth factors - from cloning to therapeutics abs#013

4:45pm

Pierre Dilda

From the bench to the bedside with a novel class of anti-mitochondrial cancer dugs abs#014

Buses to Conference Dinner Depart

5:40 PM

Crowne Plaza Hotel

6:00 PM

The Gemini Hotel

Conference Dinner

7:00 PM - 11:30 PM

WatersEdge

Tuesday, 18 May 2010

Registration

8:00 AM - 5:30 PM

Venue Foyer

Drug Development & Targeting

8:30 AM - 10:30 AM

Pfizer Australia Lecture Theatre

Chair: Alan Robertson and Geoff Symonds

8:30am **Alan Robertson** - Overview

8:45am **Peter Houghton**

Developing Novel Therapies for Childhood Cancer: Cumulative Results and Future Directions for the Pediatric Preclinical Testing Program *abs#015*

9:30am **Andrew Wilks**

The JAK Family of PTKs as Targets for Therapeutic Drugs *abs#016*

10:00am **Stephan Grant**

Pfizer Oncology Drug Discovery: A collaborative approach *abs#017*

Morning Tea

10:30 AM - 11:00 AM

Tyree Room

Targeting Cell Survival & Proliferation

11:00 AM - 12:30 PM

Pfizer Australia Lecture Theatre

Chair: Karen MacKenzie and Jamie Fletcher

11:00am **John Maris**

Genomic dissection of neuroblastoma: New therapies emerge *abs#018*

11:45am **Roger Reddel**

Telomere length maintenance mechanisms as a target for cancer therapy *abs#019*

12:15pm **Kylie Mason**

The BH3 mimetic, ABT-737, is effective against Bcl-2 overexpressing lymphoid tumors *abs#020*

Lunch

12:30 PM - 1:30 PM

Tyree Room

Predicting Therapeutic Response

1:30 PM - 3:00 PM

Pfizer Australia Lecture Theatre

Session sponsored by Industry and Investment NSW - Office for Science and Medical Research

Chair: Richard Lock and Robyn Ward

1:30pm **Nicholas Dracopoli**

Enabling personalized medicine through application of biomarkers in clinical development *abs#021*

2:30pm **Grant McArthur**

Drugging the Undruggable : How can we treat Myc-Driven Malignancies *abs#022*

Afternoon Tea

3:00 PM - 3:30 PM

Tyree Room

Drug Development from Lab to Clinic II

3:30 PM - 5:15 PM

Pfizer Australia Lecture Theatre

Session sponsored by Cancer Therapeutics CRC

Chair: Murray Norris and Peter Gunning

3:30pm

Andrei Gudkov

Targeting "undruggable" targets in cancer abs#023

4:15pm

Andrew Roberts

Targetting lymphoid malignancies with Bcl-2 inhibitory BH3 mimetics: from proof-of-principle to clinical trials abs#024

4:45pm

Andrew Scott

Development of a Novel anti-EGFR Humanised Antibody - the Complex Path from Academia to Industry abs#025

Close - Award Presentations

5:15 PM - 5:30 PM

Pfizer Australia Lecture Theatre

Chair: Murray Norris